Abpro Holdings, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ABP Nasdaq 2830 abpro.co

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Abpro Holdings, Inc.

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers - Dec 15th, 2025 5:00 am
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives - Dec 9th, 2025 5:00 am
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager - Nov 4th, 2025 7:15 am
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - Nov 3rd, 2025 5:00 am
BC-Most Active Stocks - Aug 5th, 2025 8:30 am
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager - Apr 27th, 2025 12:00 pm
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - Mar 25th, 2025 2:30 pm
Abpro Statement on the Departure of Former CEO Ian Chan - Mar 10th, 2025 4:34 pm